Botulinum toxin in motor disorders

Anna Rita Bentivoglio, Alberto Albanese

Research output: Contribution to journalArticle

Abstract

Advances in the clinical use of botulinum neurotoxins continue. Of interest to the neurologist is the advanced practice in the treatment of focal dystonia and the new developments on other dyskinesias and on autonomic control of smooth muscle motility. New toxin serotypes are now being tested; their availability will improve clinical practice and will possibly lead to combined treatments. Indications in spasticity and in juvenile cerebral palsy are now under scrutiny. The combination of focal chemodenervation with specific rehabilitation procedures enables new development in this field.

Original languageEnglish
Pages (from-to)447-456
Number of pages10
JournalCurrent Opinion in Neurology
Volume12
Issue number4
DOIs
Publication statusPublished - 1999

Fingerprint

Botulinum Toxins
Dystonic Disorders
Nerve Block
Dyskinesias
Neurotoxins
Cerebral Palsy
Smooth Muscle
Rehabilitation
Therapeutics
Motor Disorders
Serogroup
Neurologists

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Botulinum toxin in motor disorders. / Bentivoglio, Anna Rita; Albanese, Alberto.

In: Current Opinion in Neurology, Vol. 12, No. 4, 1999, p. 447-456.

Research output: Contribution to journalArticle

Bentivoglio, Anna Rita ; Albanese, Alberto. / Botulinum toxin in motor disorders. In: Current Opinion in Neurology. 1999 ; Vol. 12, No. 4. pp. 447-456.
@article{c75f56bfb34f4ede9218b091c89671e7,
title = "Botulinum toxin in motor disorders",
abstract = "Advances in the clinical use of botulinum neurotoxins continue. Of interest to the neurologist is the advanced practice in the treatment of focal dystonia and the new developments on other dyskinesias and on autonomic control of smooth muscle motility. New toxin serotypes are now being tested; their availability will improve clinical practice and will possibly lead to combined treatments. Indications in spasticity and in juvenile cerebral palsy are now under scrutiny. The combination of focal chemodenervation with specific rehabilitation procedures enables new development in this field.",
author = "Bentivoglio, {Anna Rita} and Alberto Albanese",
year = "1999",
doi = "10.1097/00019052-199908000-00012",
language = "English",
volume = "12",
pages = "447--456",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Botulinum toxin in motor disorders

AU - Bentivoglio, Anna Rita

AU - Albanese, Alberto

PY - 1999

Y1 - 1999

N2 - Advances in the clinical use of botulinum neurotoxins continue. Of interest to the neurologist is the advanced practice in the treatment of focal dystonia and the new developments on other dyskinesias and on autonomic control of smooth muscle motility. New toxin serotypes are now being tested; their availability will improve clinical practice and will possibly lead to combined treatments. Indications in spasticity and in juvenile cerebral palsy are now under scrutiny. The combination of focal chemodenervation with specific rehabilitation procedures enables new development in this field.

AB - Advances in the clinical use of botulinum neurotoxins continue. Of interest to the neurologist is the advanced practice in the treatment of focal dystonia and the new developments on other dyskinesias and on autonomic control of smooth muscle motility. New toxin serotypes are now being tested; their availability will improve clinical practice and will possibly lead to combined treatments. Indications in spasticity and in juvenile cerebral palsy are now under scrutiny. The combination of focal chemodenervation with specific rehabilitation procedures enables new development in this field.

UR - http://www.scopus.com/inward/record.url?scp=0033396650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033396650&partnerID=8YFLogxK

U2 - 10.1097/00019052-199908000-00012

DO - 10.1097/00019052-199908000-00012

M3 - Article

C2 - 10555834

AN - SCOPUS:0033396650

VL - 12

SP - 447

EP - 456

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 4

ER -